跳至主要内容
临床试验/NCT03349528
NCT03349528Enrolling By Invitation2 期

A Double-Blind Placebo-Controlled Trial of a Probiotic Supplement to Prevent Relapse and Improve the Clinical Course After Hospitalization for Bipolar Depression

Sheppard Pratt Health System2 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2018年12月11日最近更新:
适应症

试验速览

阶段
2 期
状态
Enrolling By Invitation
发起方
入组人数
80
试验地点
2
主要终点
Time to Relapse

研究概览

简要总结

The purpose of this study is to determine if taking a probiotic supplement versus a placebo will reduce relapse and improve the clinical course among participants who have been hospitalized for bipolar depression.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age 18-65 (inclusive)
  • Capacity for written informed consent
  • Currently (or within the last 3 weeks) admitted to a Sheppard Pratt inpatient or day hospital program for symptoms of a depressive episode and a diagnosis Bipolar Disorder I or II, most recent episode depressed per Diagnostic and Statistical Manual of Mental Disorders 5th Edition (DSM-5), the diagnosis of which is confirmed with the Structured Clinical Interview for DSM-5 Disorders (SCID-5)
  • Proficient in the English language
  • Available to come to Sheppard Pratt Towson for study visits after hospital discharge

排除标准

  • Depressive symptoms better accounted for by a diagnosis of Major Depressive Disorder, Schizoaffective disorder, Schizophrenia, or disorder(s) other than Bipolar Disorder I or II
  • DSM-5 diagnosis of intellectual disability or comparable diagnosis determined by previous version of the DSM
  • Substance- or medically-induced mood symptoms at time of Visit 1/Baseline visit
  • DSM-5 diagnosis of a moderate or severe substance use disorder, except for caffeine or tobacco, within three months prior to the Visit 1/Baseline visit
  • History of IV drug use
  • Any clinically significant or poorly controlled medical disorder as determined by the principal investigator and/or the study physician (e.g., HIV infection or other immunodeficiency condition, uncontrolled diabetes, congestive heart failure)
  • A serious medical condition that affects brain or cognitive functioning (e.g., epilepsy, serious head injury, concussion involving loss of consciousness, brain tumor, or other neurological disorder)
  • Pregnant, planning to become pregnant, or breastfeeding during the study period
  • Documented celiac disease
  • Participated in any investigational drug trial in the 30 days prior to the Visit 1/Baseline visit
  • Receipt of Electroconvulsive therapy (ECT) in the 30 days prior to the Visit 1/Baseline visit or planned ECT after hospital discharge

结局指标

主要结局

Time to Relapse

时间窗: Weeks 0 - 24 of study participation

Time to relapse defined as time until psychiatric rehospitalization during the study period

次要结局

  • Montgomery-Åsberg Depression Rating Scale (MADRS)(Weeks 0 - 24 of study participation)
  • New Mood Episodes(Weeks 0 - 24 of study participation)
  • Hamilton Depression Rating Scale(Weeks 0 - 24 of study participation)
  • Young Mania Rating Scale(Weeks 0 - 24 of study participation)
  • Columbia-Suicide Severity Rating Scale(Weeks 0 - 24 of study participation)
  • Brief Psychiatric Rating Scale(Weeks 0 - 24 of study participation)

研究者

发起方
Sheppard Pratt Health System
申办方类型
Other
责任方
Principal Investigator
主要研究者

Faith Dickerson

Principal Investigator, Stanley Research Program

Sheppard Pratt Health System

研究点 (2)

Loading locations...

相似试验